Chronic Rapamycin Treatment Causes Glucose Intolerance and Hyperlipidemia by Upregulating Hepatic Gluconeogenesis and Impairing Lipid Deposition in Adipose Tissue
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The mammalian target of rapamycin (mTOR)/p70 S6 kinase 1 (S6K1) pathway is a critical signaling component in the development of obesity-linked insulin resistance and operates a nutrient-sensing negative feedback loop toward the phosphatidylinositol 3-kinase (PI 3-kinase)/Akt pathway. Whereas acute treatment of insulin target cells with the mTOR complex 1 (mTORC1) inhibitor rapamycin prevents nutrient-induced insulin resistance, the chronic effect of rapamycin on insulin sensitivity and glucose metabolism in vivo remains elusive. RESEARCH DESIGN AND METHODS: To assess the metabolic effects of chronic inhibition of the mTORC1/S6K1 pathway, rats were treated with rapamycin (2 mg/kg/day) or vehicle for 15 days before metabolic phenotyping. RESULTS: Chronic rapamycin treatment reduced adiposity and fat cell number, which was associated with a coordinated downregulation of genes involved in both lipid uptake and output. Rapamycin treatment also promoted insulin resistance, severe glucose intolerance, and increased gluconeogenesis. The latter was associated with elevated expression of hepatic gluconeogenic master genes, PEPCK and G6Pase, and increased expression of the transcriptional coactivator peroxisome proliferator–activated receptor-γ coactivator-1α (PGC-1α) as well as enhanced nuclear recruitment of FoxO1, CRTC2, and CREB. These changes were observed despite normal activation of the insulin receptor substrate/PI 3-kinase/Akt axis in liver of rapamycin-treated rats, as expected from the blockade of the mTORC1/S6K1 negative feedback loop. CONCLUSIONS: These findings unravel a novel mechanism by which mTORC1/S6K1 controls gluconeogenesis through modulation of several key transcriptional factors. The robust induction of the gluconeogenic program in liver of rapamycin-treated rats underlies the development of severe glucose intolerance even in the face of preserved hepatic insulin signaling to Akt and despite a modest reduction in adiposity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Specifically, compensatory pathways are activated in response to chronic rapamycin treatment [66, 67].”
From AMPK hyperactivation promotes dendrite retraction, synaptic loss, and neuronal dysfunction in glaucoma (2021) · cites this paper as [67]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
TOR signaling in growth and metabolism
Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787 · cited 3×
“Diabetes 59:1338–1348, 2010 The mammalian target of rapamycin (mTOR) is a Ser/Thr kinase that belongs to the phosphatidylinositol (PI) kinase-related protein kinase family (1).”
BackgroundWatterson, K. R., Bestow, D., Gallagher, J., Hamilton, D. L., Ashford, F. B., Meakin, P. J., & Ashford, M. L. J. (2013) · Neurosignals · doi:10.1159/000334144 · Cited by 3,389
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365
Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1
Yoon, J. C., Puigserver, P., Chen, G., Donovan, J., Wu, Z., Rhee, J., Adelmant, G., Stafford, J., Kahn, C. R., Granner, D. K., et al. (2001) · Nature · doi:10.1038/35093050 · Cited by 1,821 · cited 1×
“We also found that rapamycin markedly increases PGC-1 mRNA expression, which likely contributes to the upregulation of the gluconeogenic enzymes, as observed in type 2 diabetes (32).”
BackgroundAbsence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity
Um, S. H., Frigerio, F., Watanabe, M., Picard, F., Joaquin, M., Sticker, M., Fumagalli, S., Allegrini, P. R., Kozma, S. C., Auwerx, J., et al. (2004) · Nature · doi:10.1038/nature02866 · Cited by 1,677
mTOR controls mitochondrial oxidative function through a YY1–PGC-1α transcriptional complex
Cunningham, J. T., Rodgers, J. T., Arlow, D. H., Vazquez, F., Mootha, V. K., & Puigserver, P. (2007) · Nature · doi:10.1038/nature06322 · Cited by 1,488
Insulin-regulated hepatic gluconeogenesis through FOXO1–PGC-1α interaction
Puigserver, P., Rhee, J., Donovan, J., Walkey, C. J., Yoon, J. C., Oriente, F., Kitamura, Y., Altomonte, J., Dong, H., Accili, D., et al. (2003) · Nature · doi:10.1038/nature01667 · Cited by 1,487
CREB regulates hepatic gluconeogenesis through the coactivator PGC-1
Herzig, S., Long, F., Jhala, U. S., Hedrick, S., Quinn, R., Bauer, A., Rudolph, D., Schutz, G., Yoon, C., Puigserver, P., et al. (2001) · Nature · doi:10.1038/35093131 · Cited by 1,440 · cited 1×
“CREB may also promote gluconeogenesis through increased PGC-1 expression (43).”
BackgroundGuertin, D. A., Stevens, D. M., Thoreen, C. C., Burds, A. A., Kalaany, N. Y., Moffat, J., Brown, M., Fitzgerald, K. J., & Sabatini, D. M. (2006) · Developmental Cell · doi:10.1016/j.devcel.2006.10.007 · Cited by 1,415 · cited 1×
“GSK-3 phosphorylation was recently found to be preserved despite complete loss of Akt Ser473 phosphorylation in mouse embryo fibroblasts from rictor knockout animals (49).”
BackgroundPeterson, T. R., Laplante, M., Thoreen, C. C., Sancak, Y., Kang, S. A., Kuehl, W. M., Gray, N. S., & Sabatini, D. M. (2009) · Cell · doi:10.1016/j.cell.2009.03.046 · Cited by 1,202 · cited 1×
“The mTOR complex 1 (mTORC1) is composed of mTOR, G L, PRAS40, deptor, and raptor and regulates cell growth, whereas the complex 2 (mTORC2) consists of mTOR, G L, protor-1, mSIN1, deptor, and rictor and controls cytoskeleton regulation and cell survival (1,2).”
Background
Research works printed but not linked: 1
- Hamada, Upregulation of the mTOR complex 1 pathway by Rheb in pancreatic β cells leads to increased β cell mass and prevention of hyperglycemia, Diabetes
Cited by
Items 301–400 of 463
Yang, Y., Qi, Q., Wang, Y., Shi, Y., Yang, W., Cen, Y., Zhu, E., Li, X., Chen, D., & Wang, B. (2018) · The FASEB Journal · doi:10.1096/fj.201700830rr · Cited by 13
Besançon, A., Goncalves, T., Valette, F., Mary, C., Vanhove, B., Chatenoud, L., & You, S. (2018) · Diabetologia · doi:10.1007/s00125-018-4638-7 · Cited by 12
Treatment: Symptomatic treatment of hypoglycaemia
Tabarin, A., & Goichot, B. (2013) · Annales d Endocrinologie · doi:10.1016/j.ando.2013.05.009 · Cited by 13
mTOR inhibitors for treatment of low-risk prostate cancer
Liss, M. A., Rickborn, L., DiGiovanni, J., Bacich, D. J., deGraffenried, L. A., Parihar, M., Thompson, I. M., & Sharp, Z. D. (2018) · Medical Hypotheses · doi:10.1016/j.mehy.2018.06.004 · Cited by 12
Antoch, M. P., Wrobel, M. M., Gillard, B. M., Kuropatwinski, K. K., Toshkov, I. A., Gleiberman, A. S., Karasik, E., Moser, M. T., Foster, B. A., Andrianova, E. L., et al. (2020) · Oncotarget · doi:10.18632/oncotarget.27550 · Cited by 12
Benedini, S., Ermetici, F., Briganti, S., Codella, R., Terruzzi, I., Maffi, P., Caldara, R., Secchi, A., Nano, R., Piemonti, L., et al. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1141-z · Cited by 13
Aging and Diabetic Kidney Disease: Emerging Pathogenetic Mechanisms and Clinical Implications
Chen, Y., Kanwar, Y. S., Chen, X., & Zhan, M. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867330666230621112215 · Cited by 12
Framarino‐dei‐Malatesta, M., Derme, M., Napoli, A., Iaria, G., Manzia, T. M., Orlando, G., Casorelli, A., & Berloco, P. B. (2014) · Transplantation Proceedings · doi:10.1016/j.transproceed.2014.07.047 · Cited by 11
Kokuho, N., Terasaki, Y., Kunugi, S., Saito, Y., Urushiyama, H., Terasaki, M., Hayashi, H., Gemma, A., & Shimizu, A. (2019) · Laboratory Investigation · doi:10.1038/s41374-018-0158-9 · Cited by 11
Das, F., Ghosh‐Choudhury, N., Maity, S., Kasinath, B. S., & Choudhury, G. G. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102246 · Cited by 12
Song, Q., Chen, Y., Ding, Q., Griffiths, A., Liu, L., Park, J., Liew, C. W., Nieto, N., Li, S., Dou, X., et al. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000059 · Cited by 11
“[27,37] Meanwhile, mTORC1 activity is required to restrain adipose tissue lipolysis activation, mechanistically accounting for clinically observed dyslipidemia caused by rapamycin treatment.[28,38] In accordance, mTORC1 inhibition, either genetically or pharmacologically, has been associated with enhanced adipose tiss…”
BackgroundVernieri, C., Nichetti, F., Lalli, L., Moscetti, L. I., Giorgi, C. A., Griguolo, G., Marra, A., Randon, G., Rea, C. G., Ligorio, F., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4928 · Cited by 10
Spada, F., Rossi, R. E., Kara, E., Laffi, A., Massironi, S., Rubino, M., Grimaldi, F., Bhoori, S., & Fazio, N. (2021) · Pharmaceuticals · doi:10.3390/ph14060539 · Cited by 10
p21WAF1/CIP1Expression is Differentially Regulated by Metformin and Rapamycin
Molnár, Z., Millward, A., Tse, W., & Demaine, A. G. (2014) · International Journal of Chronic Diseases · doi:10.1155/2014/327640 · Cited by 13
“These findings provide support for the hypothesis that AMPK activation may regulate p21 expression, which may have implications for diabetic nephropathy and other age-related pathologies.”
BackgroundAkoum, S. E., Haddad, Y., & Couture, R. (2017) · Obesity Science & Practice · doi:10.1002/osp4.117 · Cited by 12
“This process is a main physiological remodelling of the adipose tissue responsible of the glycaemic and lipidic homeostasis improvement (31).”
BackgroundEnhanced mTOR complex 1 signaling attenuates diabetic cardiac injury in OVE26 mice
Xu, X., Kobayashi, S., Timm, D. J., Huang, Y., Zhao, F., Shou, W., & Liang, Q. (2019) · The FASEB Journal · doi:10.1096/fj.201901206r · Cited by 10
Leflunomide alleviates obesity via activation of the TAK1‐AMPK pathway and induction of lipophagy
Ji, X., Chen, J., You, C., Sun, J. F., & Xu, X. (2023) · The FASEB Journal · doi:10.1096/fj.202301162r · Cited by 9
“30 Unlike rapamycin that aggra-vates hyperglycemia in diabetic model animals, 31 A77 1726 sensitizes insulin receptors and reduces blood glucose in type 2 diabetes mouse models.”
BackgroundFasting and Fasting Mimicking Diets in Obesity and Cardiometabolic Disease Prevention and Treatment
Mishra, A. K., & Longo, V. D. (2022) · Physical Medicine and Rehabilitation Clinics of North America · doi:10.1016/j.pmr.2022.04.009 · Cited by 11
Sereno, J., Parada, B., Rodrigues‐Santos, P., Lopes, P. C., Carvalho, E., Vala, H., Teixeira‐Lemos, E., Alves, R., Figueiredo, A., Mota, A., et al. (2013) · Transplantation Proceedings · doi:10.1016/j.transproceed.2013.02.085 · Cited by 9
de Freitas, D. N., Gassen, R. B., Fazolo, T., & de Souza, A. P. D. (2016) · Toxicology in Vitro · doi:10.1016/j.tiv.2016.07.016 · Cited by 9
Implications of maraviroc and/or rapamycin in a mouse model of fragility
Pérez‐Martínez, L., Romero, L., Muñoz-Galván, S., Verdugo‐Sivianes, E. M., Rubio-Mediavilla, S., Oteo, J. A., Carnero, A., & Blanco, J. R. (2020) · Aging · doi:10.18632/aging.103167 · Cited by 10
SHP-1 phosphatase acts as a coactivator of PCK1 transcription to control gluconeogenesis
Kumar, A., Schwab, M. G., Labrada, B. L., Silveira, M. A. D., Goudreault, M., Fournier, É., Bellmann, K., Beauchemin, N., Gingras, A., Bilodeau, S., et al. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105164 · Cited by 9
Self-citationThe Clinical Pharmacology and Toxicity Profile of Rapalogs
Su, D. W., Mita, M. M., & Mita, A. C. (2015) · Springer eBooks · doi:10.1007/978-2-8178-0492-7_8 · Cited by 9
“Despite the loss in fat mass, chronic rapamycin treatment also caused glucose intolerance and insulin resistance mainly by inducing transcriptional activation of gluconeogenic genes through coordinated activation of the transcription factors PPARYγ coactivator-1α (PGC-1α), forkhead box O1 (FoxO1), cAMP response elemen…”
BackgroundPan, Q., Qin, T., Gao, Y., Li, S., Li, D., Peng, M., Zhai, H., & Xu, G. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.12.014 · Cited by 9
Kandror, K. V. (2017) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000352 · Cited by 8
Rapamycin Does Not Compromise Exercise‐Induced Muscular Adaptations in Female Mice
Elliehausen, C. J., Olszewski, S. S., Shult, C. G., Ailiani, A. R., Trautman, M. E., Babygirija, R., Lamming, D. W., Hornberger, T. A., Minton, D. M., & Konopka, A. R. (2025) · Aging Cell · doi:10.1111/acel.70183 · Cited by 8
“These results are paradoxical to previous reports suggesting rapamycin decreased adiposity in sedentary animals, particularly in diet-induced obesity models (Houde et al. 2010).”
Drolet, M., Desbiens-Brassard, V., Roussel, É., Tu, V., Couët, J., & Arsenault, M. (2015) · SpringerPlus · doi:10.1186/s40064-015-1230-1 · Cited by 8
Song, E. J., Ahn, S., Min, S., Ha, J., & Oh, G. T. (2021) · BMB Reports · doi:10.5483/bmbrep.2021.54.3.136 · Cited by 8
Geroprotectors and Skeletal Health: Beyond the Headlines
Rayson, A., Boudiffa, M., Naveed, M., Griffin, J., Dall’Ara, E., & Bellantuono, I. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.682045 · Cited by 10
Peripheral tissular analysis of rapamycin’s effect as a neuroprotective agent in vivo
González-Alcocer, A., Gopar‐Cuevas, Y., Soto‐Domínguez, A., Loera‐Arias, M. D. J., Cárdenas, O. S., Montes‐de‐Oca‐Luna, R., Rodríguez‐Rocha, H., & García‐García, A. (2022) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-022-02276-6 · Cited by 8
Zhu, Z., Xu, S., Ren, J., Jiang, T., Zhang, C., & Yan, Z. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01907-y · Cited by 8
“Anticancer drugs that inhibit phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling has been discovered to induce hyper-lipidemia [9–12].”
BackgroundVerzoni, E., de Braud, F., Fabiani, F., Grassi, P., Testa, I., & Procopio, G. (2013) · Future Oncology · doi:10.2217/fon.13.150 · Cited by 8
“The mTOR complex is a well-known regulator of cellular metabolism; in vivo data suggest that it blocks the cellular glucose uptake leading to high-level glycemia, cholesterolemia and triglyceridemia [30].”
BackgroundSirolimus for the treatment of lymphangioleiomyomatosis
Singla, A., Gupta, N., Apewokin, S. K., & McCormack, F. X. (2017) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2017.1391089 · Cited by 9
“It also promotes insulin resistance, glucose intolerance, and gluconeogenesis [73].”
BackgroundCorona, S. P., Giudici, F., Jérusalem, G., Ciruelos, E., Strina, C., Sirico, M., Bernocchi, O., Milani, M., Dester, M., Ziglioli, N., et al. (2020) · Oncotarget · doi:10.18632/oncotarget.27612 · Cited by 8
Autophagy: mechanisms, roles in human diseases, and therapeutic perspectives
He, J., & Qi, T. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1776289 · Cited by 8
Severe Hypertriglyceridemia Associated With Everolimus Treatment After Heart Transplantation
Lo, P., Kearney, K. L., Muir, C. A., Song, N., Eisman, J. A., & Macdonald, P. S. (2020) · AACE Clinical Case Reports · doi:10.4158/accr-2020-0191 · Cited by 7
“As a result, the ability for adipose tissue to clear lipids from plasma is impaired (2,3).”
BackgroundZhang, Y., Wang, H., Xu, C., Ye, X., Nan, Y., Hu, X., Fan, J., Wang, X., & Ju, D. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125291 · Cited by 7
Zhang, Y., Naaz, A., Cheng, T. Y. N., Lin, J. J., Gao, M., Dorajoo, R., & Alfatah, M. (2025) · Communications Biology · doi:10.1038/s42003-025-08178-6 · Cited by 10
Tissue-restricted inhibition of mTOR using chemical genetics
Wassarman, D. R., Bankapalli, K., Pallanck, L. J., & Shokat, K. M. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2204083119 · Cited by 7
“However, the beneficial effects of rapamycin remain coupled to toxicities that limit its broader clinical application, including insulin resistance (5, 6) and impaired wound healing (7), which result from on-target inhibition of mTOR.”
BackgroundHan, L., Wu, Y., Liu, F., & Zhang, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23136932 · Cited by 8
Mammalian Target of Rapamycin Inhibitors in Organ Transplantation
Langone, A. J., & Helderman, J. H. (2012) · CHEST Journal · doi:10.1378/chest.12-1247 · Cited by 7
Schreiber, K. H., O’Leary, M. N., & Kennedy, B. K. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-411596-5.00002-2 · Cited by 7
The Role of S6K1 in Aging and Alzheimer’s Disease: Mechanistic Insights and Therapeutic Potential
Oddo, S., Lanza, M., Casili, G., & Caccamo, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26135923 · Cited by 6
“However, because rapamycin inhibits the entire mTORC1 complex, its long-term use is associated with metabolic side effects, including dyslipidemia and immune suppression [130,131].”
Pharmacologic Means of Extending Lifespan
Lamming, D. W., Sabatini, D. M., & Baur, J. A. (2012) · Journal of Clinical & Experimental Pathology · doi:10.4172/2161-0681.s4-002 · Cited by 7
“These correlations make it somewhat surprising that rodents treated with rapamycin, despite extended lifespan, exhibit impaired glucose tolerance and insulin resistance, caused in part by increased hepatic gluconeogenesis [112,113].”
BackgroundHaematological Drugs Affecting Lipid Metabolism and Vascular Health
Parrella, A., Iannuzzi, A., Annunziata, M., Covetti, G., Cavallaro, R., Aliberti, E., Tortori, E., & Iannuzzo, G. (2022) · Biomedicines · doi:10.3390/biomedicines10081935 · Cited by 6
“Sirolimus Prophylaxis of GvHD after haematopoietic stem-cell transplantation; myelodysplastic syndrome; autoimmune haemolytic anaemia mTOR inhibitor ↑ TG [60,73,74] ↑ VLDL [79] ↑ sd LDL [52] ↑ LDL [73,74] ↑ Apo CIII [60] ↑ Fatty acid binding protein [78] ↑ Gluconeogenesis [77] ↓ LPL activity [75] ↓ Clearance LDL [75,7…”
BackgroundAto, S., Oya, C., & Ogasawara, R. (2024) · PLoS ONE · doi:10.1371/journal.pone.0312859 · Cited by 6
Regulatory Mechanism of mTOR Signaling Pathway on Cell Energy Metabolism
Tan, B., Shao, F., Yin, Y., Xiao, H., & MiaoMiao, W. U. (2015) · Scientia Sinica Vitae · doi:10.1360/n052015-00132 · Cited by 9
Wang, Y., He, Z., & Li, X. (2017) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b16-00946 · Cited by 7
mTOR–mLST8 interaction: hot spot identification through quantum biochemistry calculations
de Oliveira, F. L. S., Carletti, J. V., Azevedo, F. F. N., de Sousa, F. J. F., Caetano, E. W. S., Freire, V. N., & Zanatta, G. (2020) · New Journal of Chemistry · doi:10.1039/d0nj04099a · Cited by 6
Zhang, S., Gao, Y.-F., Zhang, K., Deng, G.-R., He, G., Gao, P., Yu, Y., Yuan, Y., Xing, S., Zhao, N., et al. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.149999 · Cited by 5
Dai, C., Zhang, Y., Gong, Y., Bradley, A. T., Tang, Z., Sellick, K., Shrestha, S., Spears, E., Covington, B. A., Stanley, J. E., et al. (2024) · iScience · doi:10.1016/j.isci.2024.111447 · Cited by 6
“Treatment with IgG in the presence or absence of mTORC1 inhibitor sirolimus (rapamycin) for 4 weeks significantly increased blood glucose levels as expected (Figures 4E and S9D), 40,41 and did not impact body weight (Figure S9E).”
Anti-aging properties of the aminosterols of the dogfish shark
Barbut, D., Perni, M., & ZASLOFF, M. A. (2024) · npj Aging · doi:10.1038/s41514-024-00188-8 · Cited by 5
“Like trodusquemine, rapamycin has been shown to prevent weight gain in mice and rats fed high-fat diets associated with reduced fat mass, possibly due to inhibition of lipogenesis and hepatic steatosis 107 – 110 .”
Wu, J., Hou, S. S., Wang, W., Yin, M., Cheng, N., Ge, L., Yin, J., & Xu, J. (2015) · Genetics and Molecular Research · doi:10.4238/2015.december.14.22 · Cited by 5
Calorie Restriction Mimetics: Progress and Potential
Roth, G. S., & Ingram, D. K. (2015) · Healthy ageing and longevity · doi:10.1007/978-3-319-14830-4_10 · Cited by 5
Can GLP-1RAs redefine transplantation standard of care?
Almalki, B. A. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.08.013 · Cited by 6
Lv, M., Yang, K., Wang, X., Liu, C., Zhou, H., Mai, K., & He, G. (2025) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2025.110008 · Cited by 4
Yu, A., Ma, C., & Hu, M. (2025) · Cells · doi:10.3390/cells14151153 · Cited by 4
“…lifespan in several different studies [18–22], which suggests rapamycin is a potent anti-aging drug, rapamycin also induces obvious unwanted side effects, including fatty liver [23,24], hyperlipidemia, glucose intolerance [25], and immune suppression that increases the risk of infections [26].”
The geroprotective potential of chalcones
Carmona‐Gutiérrez, D., Zimmermann, A., Kroemer, G., & Madeo, F. (2025) · Nature Communications · doi:10.1038/s41467-025-64167-7 · Cited by 4
Effect of rapamycin on repeated immobilization stress-induced immune alterations in the rat spleen
Rokytová, I., Mravec, B., Lauková, M., & Vargovič, P. (2020) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2020.577309 · Cited by 5
High glucose couples DJ-1 with PTEN to activate PDGFRβ for renal proximal tubular cell injury
Das, F., Ghosh‐Choudhury, N., Kasinath, B. S., Sharma, K., & Choudhury, G. G. (2025) · PLoS ONE · doi:10.1371/journal.pone.0311828 · Cited by 5
Rapamycin impacts positively on longevity, despite glucose intolerance induction
Piguet, A., Martins, P. J. F., & Kozma, S. C. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.06.038 · Cited by 4
“It was demonstrated that chronic treatment with rapamycin caused glucose intolerance in humans and rodents [7,8].”
BackgroundmTOR in Diabetic Nephropathy and Retinopathy
Fernandes, R., & Reis, F. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802733-2.00001-3 · Cited by 4
2-Oxonanonoidal Antibiotic Actinolactomycin Inhibits Cancer Progression by Suppressing HIF-1α
Cheng, J., Hu, L., Yang, Z., Suo, C., Wang, Y. J., Gao, P., Cui, C., & Sun, L. (2019) · Cells · doi:10.3390/cells8050439 · Cited by 6
“In addition, chronic rapamycin administration results in a diabetes-like syndrome due to hyperlipidemia, glucose intolerance, and reduced fat mass [37].”
BackgroundA high-dose rapamycin treatment alleviates hepatopulmonary syndrome in cirrhotic rats
Chang, C.-C., Chuang, C., Hsin, I., Hsu, S., Huang, H., Lee, F., & Lee, S. (2019) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000194 · Cited by 4
Tu, G., Dai, C., Qu, H., Wang, Y., & Liao, B. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11362 · Cited by 5
Lamming, D. W. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-823679-6.00002-3 · Cited by 4
Interactions Among mTORC, AMPK and SIRT A Computational Model for Cell Energy Balance and MetabolismPreprint
Sadria, M., & Layton, A. T. (2020) · Research Square · doi:10.21203/rs.3.rs-122671/v1 · Cited by 4
Role of endothelial Raptor in abnormal arteriogenesis after lower limb ischaemia in type 2 diabetes
Liu, T., Zhang, J., Chang, F., Sun, M., He, J., & Ai, D. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae105 · Cited by 3
Das, F., Ghosh‐Choudhury, N., Kasinath, B. S., Sharma, K., & Choudhury, G. G. (2024) · Experimental Cell Research · doi:10.1016/j.yexcr.2024.114116 · Cited by 3
A Case of Successful Treatment of Severe Hyperlipidemia After Heart Transplantation With Inclisiran
Tatarintseva, Z. G., Tkhatl, L. K., Barbukhatti, K. O., & Kosmacheva, E. D. (2024) · Kardiologiia · doi:10.18087/cardio.2024.7.n2679 · Cited by 3
Everolimus treatment among patients with tuberous sclerosis affects serum lipid profile
Trelińska, J., Dachowska, I., Kotulska, K., Jóźwiak, S., Fendler, W. M., & Mlynarski, W. M. (2016) · Pharmacological Reports · doi:10.1016/j.pharep.2016.05.011 · Cited by 3
The Role of mTOR Inhibitors in Solid Organ Transplantation
McKenna, G. J., & Klintmalm, G. B. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802733-2.00023-2 · Cited by 3
Huot, M., & Richard, S. (2012) · Adipocyte · doi:10.4161/adip.20819 · Cited by 3
“The inhibition of mTORC1 is known to prevent the adipogenic differentiation of pre-adipocytes,(21,22) and to downregulate fat deposition in rodents.(23,24) Moreover, the inhibition of mTORC1 signaling in mice leads to lean phenotypes.”
BackgroundLiu, Q., Du, Q., Yuan, X., Zhang, T., Li, J., Xu, J., & Xie, R. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s539555 · Cited by 2
“32 Long term inhibition of mTORC1 by rapamycin can impair insulin secretion and cause insulin resistance.”
Immunometabolic remodeling: new perspectives and strategies for liver transplantation
Wang, L., Sheng, X., Shi, G., Li, Y., Wang, D., Wang, W., Mi, C., Wang, S., Du, Y., & 杨含腾 (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1776694 · Cited by 2
“Moreover, mTOR inhibition reduces the catabolism of circulating lipoproteins by inhibiting lipase activity, leading to dyslipidemia (60).”
mTOR signaling in liver disease
Cornu, M., de Coquereaumont, G. D. C., & Hall, M. N. (2015) · Wiley eBooks · doi:10.1002/9781118663387.ch22 · Cited by 3
Yin, Y., Fan, H., Zhang, X., Zheng, Z., Xu, J., Ming, T., Kong, F., & Jiao, L. (2024) · Aquaculture International · doi:10.1007/s10499-024-01687-x · Cited by 2
“Notably, pepck and g6pc serve as the primary rate-limiting enzymes in hepatic gluconeogenesis (Houde et al. 2010), while hk , pk , and pfk play crucial roles as rate-limiting enzymes in glycolysis, catalyzing the conversion of glucose to pyruvate (Zahra et al. 2020).”
Pereira, M. J., Eriksson, J. W., & Svensson, M. K. E. (2014) · Transplantation Proceedings · doi:10.1016/j.transproceed.2014.02.018 · Cited by 2
“Both proteins have previously been shown to be suppressed by mTOR inhibitors [13,20] and this difference between CsA and everolimus is also supported by data from animal studies [26].”
ResultmTOR in Metabolic and Endocrine Disorders
Swierczynska, M. M., & Hall, M. N. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802733-2.00008-6 · Cited by 3
Regulation of Macroautophagy by Nutrients and Metabolites
Lorin, S., Pattingre, S., Meijer, A. J., & Codogno, P. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802167-5.00014-1 · Cited by 3
Chen, Q., Chen, Y., Wang, X., Yang, H., Zhang, Y., Liu, X., Yan, Y., & Wei, H. (2020) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.galenos.2020.2020.0033 · Cited by 2
“Furthermore, long-term management with sirolimus was found to cause glucose intolerance by up-regulating hepatic gluconeogenesis (23).”
BackgroundThe caloric restriction fallacy, rodent diet aids and the tumor suppression theory of agingPreprint
Wolf, A. M. (2021) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/a2689 · Cited by 2
Effect of Sirolimus/Metformin Co-Treatment on Hyperglycemia and Cellular Respiration in BALB/c Mice
Albawardi, A. S., Saraswathiamma, D., Sharma, C., Elomami, A. S., Souid, A., & Almarzooqi, S. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021223 · Cited by 2
“The primary side effect of chronic SRL therapy is the development of glucose intolerance through increased hepatic gluconeogenesis [6].”
BackgroundEffect of sirolimus on insulin dynamics in horses
de Tonnerre, D. J., Medina‐Torres, C. E., Stefanovski, D., Robinson, M. A., Kemp, K. L., Bertin, F., & Eps, A. W. V. (2023) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.16650 · Cited by 1
“29,30,35,39 The effect of mTOR inhibitors on glucose regulation is not fully understood but has been utilized therapeutically in the management of hyperinsuline-mic hypoglycemia resulting in regulation of blood glucose in cases referrable to abnormal activation of the mTOR pathway.”
Luu, D., Shah, T., Sakharkar, P., & Min, D. I. (2023) · Transplant Immunology · doi:10.1016/j.trim.2023.101947 · Cited by 1
Aging reimagined: Bridging clinical modulation and scientific breakthroughs
Mhamdi, S., Chamari, K., BaHammam, A. S., Alkeridy, W. A., Aldeeri, A., & Saad, H. B. (2025) · Biology of Sport · doi:10.5114/biolsport.2026.156224 · Cited by 3
“…inhibition of mTORC1/S6K1 signaling is anticipated to confer beneficial effects, chronic treatment has been found to impair metabolic function [35, 36], leading to hyperlipid - emia, reduced adipose tissue mass, glucose intolerance, insulin re - sistance, and ultimately a diabetes-like phenotype…”
Tu, Y., Wang, D., Ma, J., Yu, K., Li, S., Li, B.-H., Deng, X.-Y., Li, S., Wang, H., 尹太郎, et al. (2026) · Science China Life Sciences · doi:10.1007/s11427-025-3046-4 · Cited by 1
“…as disrupted estrous cycles (Dou et al., 2017; Zhang et al., 2013),, weight loss (Zhang et al., 2013), impaired lipid and glucose metabolism, and immunosuppression (Houde et al., 2010; Janes and Fruman, 2009; Pereira et al., 2013; Piguet et al., 2012), which hinder its use in healthy populations.”
Shu, Y., Zhou, H., Wang, X., Liu, C., Mai, K., & He, G. (2026) · Aquaculture · doi:10.1016/j.aquaculture.2026.744090 · Cited by 1
Кучеров, А. А., Ershova, A. I., Novokhatskaya, E. A., Евгеньевич, С. В., & Drapkina, O. M. (2026) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2026-4776 · Cited by 2
Bench to bedside: is rapamycin headed for the docTOR?
Lamming, D. W. (2026) · GeroScience · doi:10.1007/s11357-026-02306-8 · Cited by 2
“These effects can also be observed in rodents [19, 48, 49]; however, their potential impact on aging in mice is unclear, as mice housed in laboratory facilities are protected from many pathogens, they are relatively resistant to atherosclerosis, and glucose levels may not have the same relationship…”
Raghavan, P. R. (2026) · Medical Research Archives · doi:10.18103/mra.2026.0447 · Cited by 1
A Critical Review of Steroid Immunotherapy in Kidney Transplantation
Bamgbola, O. F. (2015) · International Journal of Immunology and Immunotherapy · doi:10.23937/2378-3672/1410006 · Cited by 1
Vaiserman, A. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12295-4 · Cited by 1
Current Update on Rapamycin Production and its Potential Clinical Implications
Patel, G. K., Patel, G. K., Goyal, R., & Waheed, S. M. (2019) · Wiley eBooks · doi:10.1002/9781119460053.ch6 · Cited by 1
Rapamycin did not prevent the excessive exercise-induced hepatic fat accumulation
Pinto, A. P., da Rocha, A. L., Teixeira, G. R., Rovina, R. L., Veras, A. S. C., Frantz, F. G., Pauli, J. R., de Moura, L. P., Cintra, D. E., Ropelle, E. R., et al. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120800 · Cited by 1
Evans, J. B., Chou, L., Kaeberlein, M. R., Promislow, D., & Creevy, K. E. (2023) · Frontiers in Veterinary Science · doi:10.3389/fvets.2023.1285498 · Cited by 1
Shinagawa, F. B. (2015) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.9.2015.tde-28052015-091051 · Cited by 3
Sobczyk, M. K., & Gaunt, T. R. (2023) · medRxiv · doi:10.1101/2023.10.02.23296427 · Cited by 1
Cardiovascular Disease and Preventive Healthcare after Organ Transplantation
Pastan, S. O., & Gupta, D. (2014) · Wiley eBooks · doi:10.1002/9781118873434.ch88
Metabolic and cellular effects of calorie restriction and whey proteins in experimental obesity
Kurki, E. (2013) · Helda - University of Helsinki Institutional Repository
Metadata
- Authors
- Houde, V. P., Brûlé, S., Festuccia, W. T., Blanchard, P.-G., Bellmann, K., Deshaies, Y., & Marette, A.
- Affiliations
- Institut universitaire de cardiologie et de pneumologie de Québec (CA)
- Corresponding author
- Marette, André
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2010-03-18
- Volume
- 59
- Issue
- 6
- Pages
- 1338-1348
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC2874694
- OpenAlex
- W2153442288
- Cited by
- 456
- References
- 51
- Citations by year
- 2026: 12 · 2025: 25 · 2024: 14 · 2023: 25 · 2022: 20 · 2021: 30 · 2020: 25 · 2019: 26 · 2018: 33 · 2017: 37 · 2016: 35 · 2015: 42 · 2014: 47 · 2013: 32 · 2012: 30
- FWCI
- 10.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval
- Canadian Institutes of Health Research (144336)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- hepatic gluconeogenesis, impaired glucose tolerance, hyperlipidemia, insulin resistance, PGC-1α, FOXO1, CRTC2, CREB, PI3K/Akt signaling, phosphoenolpyruvate carboxykinase, glucose-6-phosphatase, adiposity
- MeSH terms
- Adipose Tissue, Animals, Blood Glucose, C-Peptide, Fatty Acids, Nonesterified, Glucagon, Hyperlipidemias, Immunosuppressive Agents, Insulin, Liver, Male, Pyruvates, RNA, Triglycerides, Down-Regulation, Polymerase Chain Reaction, Rats, Sprague-Dawley, Adipocytes, Glucose Intolerance, Muscle, Skeletal, Sirolimus, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.